Short-term anatomic effect of ranibizumab for polypoidal choroidal vasculopathy.
OBJECTIVE
To assess the short-term anatomic effect of intravitreal ranibizumab for polypoidal choroidal vasculopathy.


METHODS
All patients had undergone a full ophthalmic examination. A monthly injection of ranibizumab was performed for 3 months. Indocyanine angiography (ICG) and optical coherence tomography (OCT) were performed 1 month after the third-month ranibizumab injection.


RESULTS
Polyps disappeared on ICG angiography in 9 out of 13 lesions (69.2%). Retinal thickness diminished significantly on OCT (p=0.02). In our series we noticed a significant reduction of the percentage of patients presenting with subretinal fluid (p=0.02) and pigment epithelium detachment between the initial and final visits (0.016). In addition, we noticed that BCVA increased significantly (p 0.02).


CONCLUSIONS
Monthly intravitreal injection of ranibizumab for 3 months has a short-term beneficial anatomic effect.
Reche-Frutos
J
J
Hospital Clinico Universitario San Carlos, Madrid, Spain. rechejuan@yahoo.es
Calvo-Gonzalez
C
C
Donate-Lopez
J
J
Garcia-Feijoo
J
J
Leila
M
M
Garcia-Sanchez
J
J
D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002829:Choroid / Q000098:blood supply*; D015862:Choroid Diseases / Q000175:diagnosis / Q000188:drug therapy*; D005122:Exudates and Transudates; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007208:Indocyanine Green; D007267:Injections; D008297:Male; D008875:Middle Aged; D016491:Peripheral Vascular Diseases / Q000175:diagnosis / Q000188:drug therapy*; D000069579:Ranibizumab; D019233:Retreatment; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007208:Indocyanine Green; D000069579:Ranibizumab